Financial Comparison: Revolutions Medical (OTCMKTS:RMCP) & PROCEPT BioRobotics (NASDAQ:PRCT)

PROCEPT BioRobotics (NASDAQ:PRCT) and Revolutions Medical (OTCMKTS:RMCP) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 10.5% of Revolutions Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

PROCEPT BioRobotics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Revolutions Medical has a beta of -0.43, indicating that its share price is 143% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for PROCEPT BioRobotics and Revolutions Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	0	0	7	0	3.00
Revolutions Medical	0	0	0	0	N/A

PROCEPT BioRobotics currently has a consensus target price of $78.17, indicating a potential downside of 8.03%. Given PROCEPT BioRobotics’ higher probable upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Revolutions Medical.

Profitability

This table compares PROCEPT BioRobotics and Revolutions Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-58.73%	-37.85%	-26.20%
Revolutions Medical	N/A	N/A	N/A

Earnings and Valuation

This table compares PROCEPT BioRobotics and Revolutions Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$176.58 million	24.75	-$105.90 million	($2.12)	-40.09
Revolutions Medical	N/A	N/A	N/A	N/A	N/A

Revolutions Medical has lower revenue, but higher earnings than PROCEPT BioRobotics.

Summary

PROCEPT BioRobotics beats Revolutions Medical on 6 of the 9 factors compared between the two stocks.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

About Revolutions Medical

Revolutions Medical Corporation, a development stage company, is engaged in the design, development, and commercialization of auto retractable vacuum safety syringes in the United States and internationally. The company develops RevVac auto retractable vacuum safety syringe, which is designed to reduce accidental needle stick injuries and lower the spread of blood borne diseases. It is also developing a suite of magnetic resonance imaging software tools consisting of RevColor, Rev3D, RevDisplay, and RevScan that are designed to enhance general diagnostic confidence through education and research use. The company sells its products to acute care hospitals, alternate care facilities, doctors' offices, clinics, emergency centers, surgical centers, convalescent hospitals, veterans administration facilities, military organizations, public health facilities, and prisons through distributors. Revolutions Medical Corporation was founded in 1996 and is headquartered in Charleston, South Carolina.